Hyaluronidase versus verapamil as an Adjuvant to Bupivacaine in the Ultrasound-guided Serratus Anterior Block in Postoperative Pain Control for Modified Radical Mastectomy Cases

Hyaluronidase versus verapamil as an Adjuvant to Bupivacaine in the Ultrasound-guided Serratus Anterior Block in Postoperative Pain Control for Modified Radical Mastectomy Cases - Hyaluronidase versus verapamil as an Adjuvant to Serratus Anterior Block in Postoperative Pain Control for Modified Radical Mastectomy Cases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000051191

Enrollment

Registered

2024-05-29

Start date

2023-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serratus anterior block for post-operative pain in modified radical mastectomy

Interventions

the efficacy of adding verapamil 2.5 mg to Bupivacaine 0.25% ultrasound guided serratus plane block regarding primarily to time to peak analgesic effect together with duration of analgesia Adding hya

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients scheduled for modified radical mastectomy will be included in this study

Exclusion criteria

Exclusion criteria: Exclusion criteria will be any patients with allergy to any test drugs, coagulopathy, infection at the nerve block puncture site, patients on of any analgesic drug within 48 h before surgery, history of chronic pain medication use, direct chest wall trauma or history of thoracic spine surgery, sinus bradycardia, and atrioventricular block

Design outcomes

Primary

Measure	Time frame
this study is to compare the efficacy and latency of adding Hyaluronidase or verapamil to Bupivacaine 0.25% ultrasound guided serratus plane block	—

Countries

Africa

Contacts

Public ContactGhada Hassan

Menofia University Anesthesia, Intinsve care and pain management department

ghada.ibrahim@med.menofia.edu.eg00201001592001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026